RSV infects almost every child before they turn 2, and kills more than 100,000 infants worldwide each year. Machine learning ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a ...

RSV infections affect a significant number of children under age 5, with considerable disease burden in primary care and emergency departments.

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

After the COVID-19 pandemic subsided, children who were hospitalized for respiratory syncytial virus infections were older ...

With the flu season imminent, new COVID-19 and influenza vaccines are available. What’s new with the vaccines and when should ...

RSV is a highly contagious virus that affects people of all ages, from infants to adults. Its symptoms often mimic those of influenza or COVID-19, making it hard to differentiate between these ...

RSV infections cause major illness, especially in infants and older adults, and rates of infection increase with age. There are now vaccines available to prevent disease caused by RSV in adults ...